Health news
Health news top Health news

   Login  |  Register    
Health News Make AMN Your Home PageDiscussion BoardsAdvanced Search ToolMedical RSS/XML News FeedHealth news
  You are here : Health.am > Health Centers > Neurology -
Azilect cuts disability in Parkinson’s - study Azilect cuts disability in Parkinson’s - study

Azilect cuts disability in Parkinson’s - study

NeurologyMar 11, 2005

Teva Pharmaceutical Industries Ltd’s drug Azilect reduces disability in patients with advanced Parkinson’s disease, according to new research published on Friday.

Professor Olivier Rascol of University Hospital in Toulouse, France, said a clinical study involving 687 patients showed that adding the once-daily medicine, also known as rasagiline, to therapy with the drug levodopa improved patients’ motor function.

“Rasagiline achieved the two main goals of treatment after levodopa—reduced disability and decreased motor fluctuations. These properties position the drug as a favorable candidate to add to the treatment of Parkinson’s disease,” Rascol said.

His research, published in the Lancet medical journal, found that Azilect reduced so-called “off” periods—when levodopa medication stops working—by an average of 1.2 hours per day.

Azilect is one of several add-on therapies developed to enhance the effects of levodopa in patients with the degenerative brain disorder who have been on the treatment for several years and find its effect wearing off.

Dr Carl Clarke of City Hospital and Birmingham University, England, said the fact Azilect was a single once-daily pill and doctors did not have to alter dosing for each patient made it more convenient than most other additional therapies.

Azilect, which was approved in Europe last month, works by blocking the breakdown of dopamine, a substance in the brain needed to facilitate movement.

Israel’s Teva and Danish drugmaker H. Lundbeck A/S will co-promote the product in Europe.

In the United States, where an application is still pending with the Food and Drug Administration, the drug will be sold by Teva and Eisai Co Ltd.

SOURCE: Lancet, March 12, 2005.

Provided by ArmMed Media
Revision date: July 4, 2011
Last revised: by Andrew G. Epstein, M.D.

Azilect cuts disability in Parkinson’s - study Bookmark this! Azilect cuts disability in Parkinson’s - study

RELATED STORIES:


 Comments [ + Post Your Own

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]




We are pleased to let readers post comments about an article. Please increase the credibility of your post by including your full name and email.

All comments are reviewed by our editors before they are posted on the site. Just keep it clean, kids.

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

Please enter the word you see in the image below:


   [advanced search]   
What health info have you recently searched for online?
Disease or condition
Exercise or fitness
Diet, nutrition or vitamins
None of the above


Get free support - Headache Causes, Symptoms, Diagnosis, and Treatment on HeadacheCare.net


Health Centers







Diabetes

















Health news
  


Health Encyclopedia

Diseases & Conditions

Drugs & Medications

Health Tools

Health Tools



   Health newsletter

  





   Medical Links



   RSS/XML News Feed



   Feedback


Add to Yahoo RSS News Feed



Google Reader




Syndicate


This website is accredited by Health On the Net Foundation. Click to verify. We comply with the HONcode standard for trustworthy health information:
Verify here.




Urology Problems and Information: Doctor-Reviewed Articles at UrologyToday.net

hit counter